Grant: Travel Awards - Institute Community Support
Centre hospitalier de l'Université de Montréal (CHUM)
$1,000.00
TP53 is a molecular switch that controls cancer cell fate decisions during ovarian cancer treatment
FY 2015-16
Summary
Advanced ovarian cancer (OCa) is particularly lethal with a 5 years survival rate below 30%. Treatment modalities include surgical tumor debulking followed by combined chemotherapies. These treatments control the disease for extended periods, but do not cure it, and are accompanied by severe side effects. We will try to understand the molecular biology behind the different responses to the chemotherapy. Ultimately, with this project we will able to identify new novel biomarkers that will help patient to choose the best treatment option
Department
Program
Travel Awards - Institute Community Support
Location
Quebec, Canada
Recipient Type
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
337289
Name
Cheng Shuofei
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Institute of Cancer Research
Projecttitle
TP53 is a molecular switch that controls cancer cell fate decisions during ovarian cancer treatment
Programtype2
Undefined
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$1,000
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Cell Death; Cell Fate; Cell Senescence; Chemotherapy; Ovarian Cancer
Abstract
Advanced ovarian cancer (OCa) is particularly lethal with a 5 years survival rate below 30%. Treatment modalities include surgical tumor debulking followed by combined chemotherapies. These treatments control the disease for extended periods, but do not cure it, and are accompanied by severe side effects. We will try to understand the molecular biology behind the different responses to the chemotherapy. Ultimately, with this project we will able to identify new novel biomarkers that will help patient to choose the best treatment option
Competitiondate
201510
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheng, Shuofei
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $1,000~ $0~
